The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Addition of venetoclax to lenalidomide and rituximab in patients with untreated MCL
Tycel Phillips, MD, City of Hope, Duarte, CA, provides an overview of a study that explored the combination of lenalidomide, rituximab, and venetoclax as a treatment regimen for untreated mantle cell lymphoma (MCL). The combination demonstrated promising results, with overall and complete response rates of 96% and 86% respectively. Furthermore, 86% of patients achieved measurable residual disease (MRD) undetectability. Nevertheless, the combination was less effective in patients with TP53 mutations. The regimen was well-tolerated, with the most common adverse events being neutropenia and thrombocytopenia. The study suggests that this combination is safe and effective for patients with untreated MCL. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
